): The elderly, who represent half of the 185,000 new cases of breast cancer and two-thirds of the deaths, have failed to realize any of the benefits of recent mortality reductions seen in younger women. At present, more than 40 percent of the elderly women who are diagnosed each year will have regional disease, where adjuvant chemotherapy can have survival benefits. The St. Gallens conference and the Steering Committee for Clinical Practice Guidelines for the Care and Treatment of Breast Cancer include recommendations for chemotherapy for elderly women. However, actual patterns of care diverge substantially from these recommendations, with only 30 percent of elderly women receiving some chemotherapy. Under use of chemotherapy is one of the key problems in the quality of cancer care recently identified by the Institute of Medicine. Patient preferences are becoming increasingly important in clinical decisions, such as chemotherapy, where benefits may be low and toxicity high. At present, we do not understand how preferences contribute to the divergence of the patterns of care and guidelines for the elderly, and we have little data concerning the outcomes of chemotherapy in this age group. To fill this gap, Lombardi Cancer Center?s Cancer and Aging and Outcomes Research programs, together with the Cancer and Leukemia Group B (CALGB) propose to study a large prospective cohort of newly-diagnosed elderly breast cancer patients with regional disease. The primary goal of this project is to use a theory-driven conceptual model of patient preferences to identify modifiable factors associated with chemotherapy decisions and subsequent quality of life and satisfaction. We are also interested in the role of co-morbidity in preferences, decisions, and outcomes. Model components have been selected to yield data that can be directly applicable to interventions and policy recommendations. Data will be collected from 1,300 women 4-6 six weeks after diagnosis in standardized telephone interviews; women will be re-interviewed 6 months, 1, 2, and up to 3 years following study entry. Records will be reviewed at baseline and annually thereafter for clinical data.
The specific aims are: 1) to describe the relationship between preferences and chemotherapy decisions, and to understand how factors which can be targets for interventions mediate this relationship; 2) to examine the relationships between preference-based chemotherapy decisions and 6-month and 1 (and 2 and 3) year quality of life, and satisfaction with treatment decisions; and 3) to describe disease-free survival. All of the potential interventions which will follow from these data can be designed for use in cooperative group settings. Interventions derived from this project, hold the promise of improving the quality of care for the fastest growing segment of the breast cancer population.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA084131-04S1
Application #
6910176
Study Section
Subcommittee G - Education (NCI)
Program Officer
Rosenfeld, Bobby
Project Start
2001-07-01
Project End
2006-05-31
Budget Start
2004-06-21
Budget End
2005-05-31
Support Year
4
Fiscal Year
2004
Total Cost
$162,688
Indirect Cost
Name
Georgetown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Mandelblatt, Jeanne S; Cai, Ling; Luta, George et al. (2017) Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat 164:107-117
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Bluethmann, Shirley M; Alfano, Catherine M; Clapp, Jonathan D et al. (2017) Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance). Breast Cancer Res Treat 165:677-686
DurĂ¡-Ferrandis, Estrella; Mandelblatt, Jeanne S; Clapp, Jonathan et al. (2017) Personality, coping, and social support as predictors of long-term quality-of-life trajectories in older breast cancer survivors: CALGB protocol 369901 (Alliance). Psychooncology 26:1914-1921
Hershman, Dawn L; Kushi, Lawrence H; Hillyer, Grace Clarke et al. (2016) Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat 157:133-43
Mandelblatt, Jeanne S; Clapp, Jonathan D; Luta, Gheorghe et al. (2016) Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). Cancer 122:3555-3563
Greenlee, Heather; Neugut, Alfred I; Falci, Laura et al. (2016) Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation: The Breast Cancer Quality of Care (BQUAL) Study. JAMA Oncol 2:1170-6
London, Laricca; Hurtado-de-Mendoza, Alejandra; Song, Minna et al. (2015) Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors. Contemp Clin Trials 40:74-80
Sheppard, Vanessa B; Faul, Leigh Anne; Luta, George et al. (2014) Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. J Clin Oncol 32:2318-27
Faul, Leigh Anne; Luta, Gheorghe; Sheppard, Vanessa et al. (2014) Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. J Cancer Surviv 8:627-37

Showing the most recent 10 out of 30 publications